Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
The potential markers of fatty liver are: oleic acid, vaccenic acid, EPA, DHA, docosapentaenoic acid, and desaturase index (SCD-18 index).
|
31752380 |
2019 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
|
31226399 |
2019 |
Fatty Liver
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
However, in obese and diabetic db/db mice hepatic steatosis was reduced and hepatic mRNA expression of acaca, scd1, fasn and pparg was significantly lower after siRNA treatment.
|
31794591 |
2019 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
The reduced ChREBP signaling correlates with down-regulation of hepatic lipogenic enzymes (ACC1, FAS, and SCD1), leading to markedly diminished hepatic steatosis in both study groups, with lower circulating cholesterol and triacylglyceride levels as well as reduced fat mass.
|
29656110 |
2018 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mice with global and skin-specific deletion (SKO) of SCD1 exhibit increased whole body energy expenditure and protection against diet-induced adiposity, hepatic steatosis, insulin sensitivity and glucose intolerance.
|
29965978 |
2018 |
Fatty Liver
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Long-term feeding of fructose in combination with SFA or TFA induced hepatic steatosis of similar extent associated with upregulation of stearoyl CoA desaturase-1.
|
28676973 |
2018 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
BAP31-deletion in hepatocytes increased the expression of SREBP1C and the target genes, including acetyl-CoA carboxylase 1 and stearoyl-CoA desaturase-1, and increased hepatic lipid accumulation and HFD-induced liver steatosis.
|
29113994 |
2018 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
Study 1 focused on regulation by five transcription factors (TFs) (NfKb, Srebp-lc, AMPK, PPARα, PPARγ) of seven, much-studied hepatic long-chain fatty acid (LCFA) transporters (FABPpm, CD36, FATPl, FATP2, FATP4, FATP5, & Caveolin-1 [CAV-1]), and expression of genes for enzymes of LCFA synthesis (SCD-1, FASN) in mice with HS from various causes.
|
27997977 |
2016 |
Fatty Liver
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
SCD1 mRNA was highly expressed in goose fatty liver, and the expression levels of SCD1 in liver and fat of overfeeding group were more than double that of the control group.
|
23124044 |
2013 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
BEFREE |
Stearoyl-CoA desaturase-1 (SCD1) has gained much interest as a future drug target to treat fatty liver and its consequences.
|
21045174 |
2011 |
Fatty Liver
|
0.300 |
Therapeutic
|
disease |
CTD_mouse |
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
|
21661758 |
2011 |